Spots Global Cancer Trial Database for Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Official Title: Fruquintinib Plus Irinotecan Second-line Treatment for Advanced Gastric Cancer: a Single-arm, Open-label, Singer-center, Phase II Study
Study ID: NCT05643677
Conditions
Study Description
Brief Summary: This study explores the efficacy and safety of fruquintinib combined with irinotecan in the second-line treatment of patients with advanced gastric cancer, aiming to bring more second-line treatment options for patients with advanced gastric cancer.
Detailed Description: This study was a single-arm, open-label, single-center phase II study. A total of 47 patients with advanced gastric cancer who had previously failed standard first-line therapy were recruited to receive combined treatment with fruquintinib and irinotecan. The patients' progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety were evaluated.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Xi Shi
Affiliation: First Affiliated Hospital of Fujian Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
